Clinical evaluation of moxalactam therapy

Frank R. Venezio*, Grant O. Westenfelder, Francis V. Cook, James E. Williams, Mary Carruthers, Boris E. Reisberg, Janet Emmerman, John P. Phair

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Moxalactam is a new β-lactam antibiotic with a long half-life and broad in-vitro activity against many aerobic and anaerobic Gram-negative bacilli including Pseudomonas aeruginosa and Bacteroides fragilis. We evaluated moxalactam clinically in 53 infected patients with significant underlying diseases. Forty-three patients (81%) responded favourably to moxalactam therapy, including fourteen with infections caused by Ps. aeruginosa. Mild side effects (skin rash, diarrhoea, and hepatic transaminase elevation) occurred in six patients. Two patients developed fungemia and one developed mild elevation of serum creatinine attributed to moxalactam which resolved after discontinuation of therapy. Seven patients with pretreatment renal dysfunction demonstrated improvement in serum creatinine while receiving moxalactam. Three organisms developed resistance during therapy. Treatment failures occurred more commonly in patients with infections due to Ps. aeruginosa with an MIC > 16 mg/l and with infections due to Gram-positive cocci. In summary, moxalactam is effective therapy for serious infections caused by susceptible Gram-negative bacilli.

Original languageEnglish (US)
Pages (from-to)435-443
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Issue number5
StatePublished - Nov 1982

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical evaluation of moxalactam therapy'. Together they form a unique fingerprint.

Cite this